Reason for request
Assessment of change of dose permitting use in children aged between 2 and 16.
Clinical Benefit
| Substantial |
The clinical benefit provided by DUROGESIC in children is substantial. |
Clinical Added Value
| Comments without ASMR value |
DUROGESIC has previously been recognised by the Transparency Committee as providing actual benefit in adults, and it provides the same benefit for children over 2. |
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
hbhK8vbjaQEjh6hK
